Nutex Health Inc. (NASDAQ:NUTX - Get Free Report) shares traded up 4.2% during trading on Friday. The stock traded as high as $210.27 and last traded at $213.1760. Approximately 16,198 shares changed hands during mid-day trading, a decline of 90% from the average session volume of 168,906 shares. The stock had previously closed at $204.59.
Analysts Set New Price Targets
A number of research firms recently weighed in on NUTX. Zacks Research upgraded shares of Nutex Health from a "hold" rating to a "strong-buy" rating in a report on Monday, August 24th. Lake Street Capital reissued a "buy" rating and set a $310.00 target price (up from $235.00) on shares of Nutex Health in a research report on Tuesday, August 11th. B. Riley Financial reissued a "buy" rating on shares of Nutex Health in a report on Friday, September 4th. Weiss Ratings upgraded Nutex Health from a "hold (c)" rating to a "hold (c+)" rating in a research report on Tuesday, July 28th. Finally, Wall Street Zen cut shares of Nutex Health from a "buy" rating to a "hold" rating in a research note on Saturday, September 5th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $317.50.
View Our Latest Stock Analysis on NUTX
Nutex Health Trading Up 7.5%
The stock's fifty day moving average price is $181.96 and its two-hundred day moving average price is $146.78. The company has a current ratio of 5.00, a quick ratio of 4.96 and a debt-to-equity ratio of 0.59. The stock has a market capitalization of $1.51 billion, a P/E ratio of 8.67 and a beta of 0.28.
Nutex Health (NASDAQ:NUTX - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported $9.38 EPS for the quarter, topping the consensus estimate of $4.95 by $4.43. The firm had revenue of $210.75 million for the quarter, compared to the consensus estimate of $215.03 million. Nutex Health had a return on equity of 39.74% and a net margin of 21.25%. Equities research analysts forecast that Nutex Health Inc. will post 27.58 EPS for the current year.
Insider Activity
In other news, Director Scott Saunders sold 203 shares of the company's stock in a transaction dated Friday, September 18th. The shares were sold at an average price of $214.25, for a total transaction of $43,492.75. Following the completion of the transaction, the director directly owned 400 shares of the company's stock, valued at approximately $85,700. This represents a 33.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 44.68% of the company's stock.
Institutional Inflows and Outflows
A number of hedge funds have recently added to or reduced their stakes in the stock. Kilter Group LLC bought a new position in Nutex Health in the second quarter worth $27,000. Islay Capital Management LLC purchased a new position in shares of Nutex Health in the 4th quarter worth $34,000. Allworth Financial LP purchased a new stake in shares of Nutex Health during the 2nd quarter valued at about $35,000. EverSource Wealth Advisors LLC purchased a new position in shares of Nutex Health during the 1st quarter worth $83,000. Finally, Mcguire Capital Advisors Inc. purchased a new stake in Nutex Health in the fourth quarter worth about $165,000. 5.32% of the stock is owned by hedge funds and other institutional investors.
About Nutex Health
(
Get Free Report)
Nutex Health Inc NASDAQ: NUTX is a physician-led healthcare services company that operates an integrated network of hospitals, outpatient facilities and physician practices. The company focuses on delivering emergency, inpatient and outpatient care through community-based healthcare facilities, including micro-hospitals designed to provide essential hospital services in convenient local settings.
Its services may include emergency medicine, primary care, specialty care, diagnostic testing, imaging, laboratory services and other ancillary healthcare offerings.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Nutex Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nutex Health wasn't on the list.
While Nutex Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.